Blue Trust Inc. Grows Stock Position in Bausch + Lomb Corporation $BLCO

Blue Trust Inc. increased its position in shares of Bausch + Lomb Corporation (NYSE:BLCO) by 58.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,502 shares of the company’s stock after purchasing an additional 1,662 shares during the quarter. Blue Trust Inc.’s holdings in Bausch + Lomb were worth $59,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Trexquant Investment LP raised its position in shares of Bausch + Lomb by 5.8% in the first quarter. Trexquant Investment LP now owns 20,255 shares of the company’s stock valued at $294,000 after buying an additional 1,108 shares during the last quarter. Woodline Partners LP grew its stake in Bausch + Lomb by 0.5% during the 1st quarter. Woodline Partners LP now owns 312,823 shares of the company’s stock valued at $4,536,000 after acquiring an additional 1,436 shares in the last quarter. Ridgewood Investments LLC purchased a new position in Bausch + Lomb in the 2nd quarter worth approximately $26,000. Gamco Investors INC. ET AL lifted its stake in Bausch + Lomb by 4.7% in the 1st quarter. Gamco Investors INC. ET AL now owns 73,100 shares of the company’s stock worth $1,060,000 after purchasing an additional 3,300 shares in the last quarter. Finally, National Bank of Canada FI boosted its holdings in shares of Bausch + Lomb by 101.7% during the 1st quarter. National Bank of Canada FI now owns 6,719 shares of the company’s stock worth $97,000 after purchasing an additional 3,387 shares during the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Bausch + Lomb in a research report on Wednesday, October 1st. They set a “neutral” rating and a $16.00 price objective on the stock. Zacks Research upgraded Bausch + Lomb to a “hold” rating in a report on Tuesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bausch + Lomb in a report on Wednesday, October 8th. HC Wainwright raised their price objective on shares of Bausch + Lomb from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Finally, Morgan Stanley boosted their target price on shares of Bausch + Lomb from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Bausch + Lomb has an average rating of “Hold” and a consensus target price of $15.70.

Bausch + Lomb Stock Up 0.8%

Shares of NYSE:BLCO opened at $14.99 on Friday. The firm’s 50-day moving average is $14.78 and its two-hundred day moving average is $13.34. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.55 and a quick ratio of 0.98. Bausch + Lomb Corporation has a 1 year low of $10.45 and a 1 year high of $21.08. The firm has a market capitalization of $5.31 billion, a PE ratio of -19.21, a price-to-earnings-growth ratio of 1.63 and a beta of 0.63.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period last year, the firm earned $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. Analysts predict that Bausch + Lomb Corporation will post 0.74 EPS for the current year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.